BMO steps to sidelines on Ambit following quizartinib news


BMO cuts Ambit Biosciences (AMBI -29.7%) to Market Perform from Outperform.

The shares are struggling mightily today on the heels of Tuesday's quizartinib news.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs